

## AMA Therapeutic Insights – CME disclosures

### Medical treatment of lower urinary tract symptoms secondary to BPH

#### Accreditation statement

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### Information on CME credit

The AMA designates this educational activity for a maximum of 1 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians should only claim credit commensurate with the extent of their participation in the activity.

It is estimated that it will take approximately 1 hour to review this material and answer the self-assessment questions online or by completing the answer sheet at the end of this newsletter and faxing or mailing according to instructions.

## CME Faculty/Benign Prostatic Hyperplasia

### Author, Reviewer and Planning Committee Disclosures

In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing healthcare goods or services relevant to the content being planned or presented. The following disclosures are provided:

#### Reginald Bruskewitz, MD, Content Reviewer

Division of Urology

University of Wisconsin School of Medicine and Public Health

Madison, WI

*Consultant, Neotract*

#### John D. McConnell, MD, Independent Reviewer

Executive VP for Health Systems Affairs

Professor of Urology

University of Texas Southwestern Medical Center

Dallas, TX

*Data monitoring committee for GlaxoSmithKline (prostate cancer prevention, unrelated to BPH)*

#### Kevin T. McVary, MD, FACS, Planning Committee/Author

Professor of Urology

Feinberg School of Medicine

Northwestern University

Chicago, IL

*Investigator and consultant, GlaxoSmithKline and Eli Lilly; Consultant, sanofi-aventis and Pfizer*

**Claus Roehrborn, MD, Content Reviewer**  
Professor and Chairman  
Department of Urology  
University of Texas Southwestern Medical Center  
Dallas, TX

*Advisor, consultant and investigator, GlaxoSmithKline, Pfizer, sanofi-aventis, Spectrum, Aeterna, Eli Lilly*

**AMA Staff**  
**R. Mark Evans, PhD, Editor/Planning Committee**  
*Nothing to disclose*

**Patti J. Fitzgerald, Managing Editor/Planning Committee**  
*Nothing to disclose*

**Laura Schmidt, Project Manager/Planning Committee**  
*Nothing to disclose*

#### **Disclosure policy**

It is the policy of the AMA to ensure balance, independence, objectivity and scientific rigor in all of its activities. This AMA CME activity has been independently planned by the AMA and complies with the AMA Division of Healthcare Products and Standards. Policies and Procedures for Resolving Conflicts of Interest (COI) for their CME activities to identify and resolve COI, review faculty and staff disclosure statements, and determine the level of participation of planning committee members, authors and reviewers.

Expiration Date: September, 2009

#### **Copyright**

Copyright © 2006-2009 American Medical Association. All rights reserved. The contents of this CME program may not be reproduced in any form without written permission from the American Medical Association. This CME program does not define a standard of care, nor is it intended to dictate an exclusive course of management. Standards of medical care are determined on the basis of all the facts and circumstances involved in an individual case and are subject to change as scientific knowledge and technology advance and patterns evolve.

[Principles for Web site privacy and confidentiality](#)

#### **Reginald Bruskewitz, MD**

Reginald Bruskewitz is Professor of Urology at the University of Wisconsin in Madison. Reg attended Medical School and completed Urology Residency at Wisconsin. He then completed a Fellowship in Female Urology and Urodynamics at the University of California Los Angeles with Dr Shlomo Raz. Reg then returned to The University of Wisconsin where his interests shifted to benign prostatic hyperplasia. He has been

involved in numerous BPH clinical trials and has studied the urodynamic aspects of prostatic disease. He is currently the Study Chair for Minimally Invasive treatment of BPH with the NIH.

**Kevin T. McVary, M.D., F.A.C.S.**

Dr. Kevin T. McVary received his Bachelor of Arts degree from Northwestern University, Evanston in 1979 and a medical degree from Northwestern University, Chicago in 1983. In 1983-1984 he completed a two-year program in general surgery at Northwestern University and Northwestern Memorial Hospital. A four-year urology training program followed. Currently he is a Professor in the Department of Urology at Northwestern University Feinberg School of Medicine. Dr. McVary divides his time conducting the Prostate Diseases Minimally Invasive Program and is Head of the Andrology Fellowship Program at Northwestern Memorial Hospital. He is an attending staff urologist at Northwestern Memorial Hospital in Chicago and a consultant with the Rehabilitation Institute of Chicago.

He holds many committee leadership positions with the National Institutes of Health to include Chairman, NIDDK Urology Study Section: NIH Sponsored MIST Trial, Chairman, NIDDK Outcomes and Data Assessment: NIH Sponsored CAMUS Trial, Member, NIDDK Urologic Complications of Diabetes Research Group, NIH, Member, NIH Planning Committee for a Clinical Research Career in Urology, Chairman, CAMUS Patient Recruitment and Forms Committee: NIH Sponsored Trial, Chairman, Patient Adherence and Recruitment Committee, NIH Sponsored MIST Trial, Reviewer for Urological/Renal Development/Urogynecological Applications in a Special Emphasis Panel (SEP) and Member, NIH/NIDDK Strategic Planning Committee for Prostate Research/Men's Health.

Dr. McVary received honors to include Recipient Award for Excellence at Jackson Hole Urology Conference, a Fellow of the American College of Surgeons and Diplomat of the American Urological Association, Chair, BPH Guidelines, American Urological Association, Chair, PGC-BPH Panel, American Urological Association, Member, American Urological Association Program Committee, Member, American Urological Association Public Media Committee, Secretary, Chicago Urological Association, and Member of the American Association of Genitourinary Surgeons.

He also serves on the Editorial Board of several journals including American Journal of Kidney Diseases, American Journal of Obstetrics and Gynecology, Journal of Andrology, Journal of Urology, Journal of Investigative Urology,, Prostate Current Reports, Current Urology Reports and Practical Reviews in Urology.

An experienced investigator in prostatic disorders and erectile dysfunction, Dr McVary has been principal investigator for more than 75 clinical trials and his research has authored more than 150 publications including refereed journal articles, books, book chapters, and abstracts. His work has appeared in prominent journals such as the *Journal of Urology*, *New England Journal of Medicine*, *International Journal of Impotence Research*, and *Urology*.

### **John D. McConnell, M.D.**

Dr. McConnell, a native Kansan and graduate of the University of Kansas, came to UT Southwestern after graduating magna cum from Loyola-Stritch School of Medicine in Chicago in 1978. After six years of training in surgery and urology, Dr. McConnell completed two years of basic research training in prostate biology with Dr. Jean D. Wilson. He joined the UT Southwestern faculty in 1984 and developed one of four NIH-funded O'Brien urology research centers in the country. Over a decade, this research center brought together basic science, clinical research and healthcare policy approaches to the field of benign prostatic hyperplasia (BPH). His specific research contributions include demonstration of the importance of the enzyme 5 $\alpha$ -reductase in the development and progression of BPH, and leadership of the landmark NIH-funded MTOPS study—which definitively established that 5 $\alpha$ -reductase therapy significantly reduces the long-term risk of clinical progression by preventing further growth of the prostate. From 1994 to 2001, Dr. McConnell served as chair of the Department of Urology at UT Southwestern, which at that time ranked 6th in America for total NIH funding. He has published more than 100 peer-reviewed articles and ten books.

Dr. McConnell is a leader in the development of evidence-based guidelines for the management of BPH. In 1990, he was commissioned by the U.S. government to develop national guidelines for the management of this disorder. Dr. McConnell has led an American Urological Association (AUA) update of the guidelines, as well as similar international projects in affiliation with the World Health Organization. Dr. McConnell has served on the AUA Board of Directors. In 1991, he received the AUA Gold Cystoscope Award. He has served on the Advisory Board of NIH-NIDDK and was elected to the Institute of Medicine of the National Academy of Sciences in 2004. He has received the Barringer Medal from the American Association of Genitourinary Surgeons and the Fuller Award from the AUA in recognition of his contributions to the field of prostate disease.

Beginning in 1999, Dr. McConnell assumed a series of executive positions in the UT Southwestern administration of increasing responsibility, ranging from academic operations to patient care. Since 2003, he has served as the Executive Vice President for Health System affairs. In that capacity he has the overall executive responsibility for the UT Southwestern faculty physician practice, University Hospitals, and outpatient clinics. This patient care enterprise has more than 900 physicians, 3000 staff, and an annual operating budget of more than \$600M. Dr. McConnell serves as President of the Southwestern Medical District (a 501c3 corporation created to coordinate the land-use and planning activities of UT Southwestern, Children's Medical Center and Parkland Hospital), and is a member of the board of directors of Dallas Medical Resource (a 501c3 created to link the north Texas business community with the area health systems to improve the care of the underserved). He serves as chair of the capital campaign for Ursuline Academy and is active in a number of civic groups.

### **Claus G. Roehrborn, MD**

Claus G. Roehrborn, MD, was born and raised in West Germany. After attending medical school in Giessen, Germany, he began his residency in surgery and urology at

the German Army Hospital in Giessen. In 1984, he came to Dallas, Texas, and continued his urology residency at The University of Texas Southwestern Medical Center at Dallas. After finishing his residency in 1989 he won an American Foundation of Urologic Disease Scholarship and worked for 2 years with Dr. Jean Wilson in the field of androgen regulation of prostate development and growth. In 1992, he joined the urology faculty at University of Texas Southwestern, where he currently is Professor and Chairman of the Department of Urology.

Dr. Roehrborn's research interests are in the areas of benign and malignant prostate diseases, including medical and minimally invasive therapies for BPH, and markers for prostate cancer. In addition, he has a background in urological ultrasound and has chaired numerous postgraduate courses and lectured on a variety of topics in ultrasound imaging of the urinary tract. His basic, translational and clinical research has yielded over 250 peer-reviewed publications, more than 30 book chapters, and numerous other contributions to the literature. Aside from being invited to give lectures all over the world, Dr. Roehrborn has chaired or participated in many postgraduate courses and has been visiting professor at leading urological institutions in the United States, Europe, and Asia.

Dr. Roehrborn has been the lead researcher for the 1994 Agency for Health Care Policy and Research (AHCPR) BPH Guidelines and has been involved in the American Urological Association (AUA) Guidelines efforts from their inception. He has chaired committees at the WHO-sponsored Consensus Conferences on BPH from 1994 through 2005 and is cochairman of the AUA BPH Guidelines Committee producing an update of the 1994 AHCPR Guidelines in 2003.

Dr. Roehrborn serves on the editorial board of many peer-reviewed journals, is associate editor of *Urology*, and coeditor of the comprehensive and authoritative *Textbook of BPH*. He is a reviewer for nearly all peer-reviewed journals in the field of urology. At present, Dr. Roehrborn continues to be involved in virtually all aspects of BPH research as well as translational and clinical research in prostatitis and prostate cancer.

Claus G. Roehrborn, MD, joined the urology faculty at The University of Texas Southwestern Medical Center in 1992 and is currently Professor and Chairman of the Department of Urology. Dr. Roehrborn's research interests are in the areas of benign and malignant prostate diseases, including medical and minimally invasive therapies for BPH, and markers for prostate cancer. His basic, translational and clinical research has yielded over 250 peer-reviewed publications, more than 30 book chapters, and numerous other contributions to the literature. He serves on the editorial board of many peer-reviewed journals, is associate editor of *Urology*, and coeditor of the comprehensive and authoritative *Textbook of BPH*. At present, Dr. Roehrborn continues to be involved in virtually all aspects of BPH research as well as translational and clinical research in prostatitis and prostate cancer.